Journals / Glokom Katarakt / 2015 / Cilt: 10 - Sayı: 1

İntravitreal Anti-VEGF Enjeksiyonu Sonrası Ön Segment Parametrelerinde Scheimpflug Camera ile Saptanan Değişimler

Alterations in Anterior Segment Parameters After Intravitreal Anti-VEGF Injection Assessed by Scheimpflug Camera

Pages
11–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The alterations in ACA returned to normal values with the decrease of IOP values after 24 hours of injection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To determine the short-term intraocular pressure (IOP) and anterior segment alterations following intravitreal injection of antivascular endothelial growth factor (anti-VEGF).Materials and Methods: A prospective series of consecutive patients undergoing injection of 0.05 mL intravitreal bevacizumab or ranibizumab, without vitreous reflux, was investigated.
📊
Key Findings & Data:Measurements were obtained in each eye just before the injection, 5 minutes after the injection and 24 hours after the injection.Results: A total of 42 eligible patients were included in this study.
💡
Conclusion & Impact:The alterations in ACA returned to normal values with the decrease of IOP values after 24 hours of injection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To determine the short-term intraocular pressure (IOP) and anterior segment alterations following intravitreal injection of antivascular endothelial growth factor (anti-VEGF).Materials and Methods: A prospective series of consecutive patients undergoing injection of 0.05 mL intravitreal bevacizumab or ranibizumab, without vitreous reflux, was investigated. IOP measurements were performed using Tono-Pen. Anterior segment parameters including anterior chamber depth (ACD), anterior chamber volume (ACV) and anterior chamber angle (ACA) were measured with the Sirius Scheimpflug camera. Measurements were obtained in each eye just before the injection, 5 minutes after the injection and 24 hours after the injection.Results: A total of 42 eligible patients were included in this study. Mean baseline IOP was 15.9±3 mmHg and it increased to 25.9±10.5 mmHg 5 minutes after the injection (p<0.001). 24 hours after the injection, IOP normalized with a value of 15±3.4 mmHg (p>0.05). Compared with baseline, changes in ACD and ACV were statistically non-significant at each time-point (p>0.05). The mean ACA decreased from 38±6.7? at baseline to 36.7±7.1? five minutes after injection (p=0.004). Mean ACA value normalized at 24 hours with a value of 37.6±7.1? (p>0.05). Conclusion: Anterior segment parameters, except ACA, seem to be unchanged after intravitreal injection. The alterations in ACA returned to normal values with the decrease of IOP values after 24 hours of injection.

Özet

Amaç: Anti-vasküler endotelyal growth factor (Anti-VEGF) enjeksiyonu sonrası kısa dönem göz içi basıncı (GİB) ve ön segment değişimlerini belirlemek.Gereç ve Yöntem: Vitreus reflüsü olmadan 0.05 ml intravitreal bevacizumab veya ranibizumab enjeksiyonu yapılan prospektif sıralı hasta serisi incelendi. GİB ölçümleri Tono-Pen ile yapıldı. Ön kamara derinliği (ÖKD), ön kamara hacmi (ÖKH) ve ön kamara açısını (ÖKA) içeren ön segment parametreleri Sirius Scheimpflug camera ile ölçüldü. Ölçümler enjeksiyondan hemen önce, enjeksiyondan 5 dakika sonra ve enjeksiyondan 24 saat sonra alındı. Bulgular: Bu çalışmaya uygun toplam 42 hasta dahil edildi. Başlangıç ortalama GİB 15.9±3 mmHg idi ve enjeksiyondan 5 dakika sonra 25.9±10.5 mmHg'ye yükseldi (p 0.05). Başlangıç ile karşılaştırıldığında herbir zaman diliminde ÖKD ve ÖKH istatistiksel olarak anlamlı değildi (p>0.05). Ortalama ÖKA, başlangıçta 38±6.7?'den enjeksiyondan 5 dakika sonra 36.7±7.1?'e düştü (p=0.004). 24 saat sonra ortalama ÖKA değeri 37.6±7.1? olarak normale döndü (p>0.05).Tartışma: İntravitreal enjeksiyon sonrası ön segment parametrelerinin, ÖKA hariç değişmediği görülmektedir. ÖKA'daki değişimler enjeksiyondan 24 saat sonra GİB değerlerinin düşmesiyle normale döndü.

🔖

Cite This Article

KARA, S., TUFAN, H. A., GENCER, B., ARIKAN, S., HONDUR, A. M., ERŞAN, İ. (2015). İntravitreal Anti-VEGF Enjeksiyonu Sonrası Ön Segment Parametrelerinde Scheimpflug Camera ile Saptanan Değişimler. Glokom Katarakt, Cilt: 10 - Sayı: 1, 11–14. https://ajindex.com/articles/200393

References (14)

  1. Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) 2012;26:1-16. 2. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF ther- apies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
  2. Wong LJ, Desai RU, Jain A et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-8.
  3. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pres- sure changes following intravitreal injections of triamcinolone, pegap- tanib, and bevacizumab. Eye 2009;23:181-5.
  4. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Oph- thalmol 2010;20:174-9.
  5. Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biome- chanical model. Acta Ophthalmol Scand 2007;85:777-81.
  6. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension fol- lowing intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-10.
  7. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-4.
  8. Kernt M, Welge-Lüssen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007;104:965-71.
  9. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pres- sure elevation after intravitreal injection of bevacizumab and ranibi- zumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-9.
  10. Freund KB, Laud K, Eandi CM, et al. Silicone oil droplets following intravitreal injection. Retina 2006;26:701-3.
  11. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 2010;248:1371-5.
  12. Goktas A, Goktas S, Atas M, et al. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pres- sure. Cutan Ocul Toxicol 2013;32:23-6.
  13. Kerimoglu H, Ozturk BT, Bozkurt B, et al. Does lens status affect the course of early intraocular pressure and anterior chamber changes af- ter intravitreal injection? Acta Ophthalmol 2011;89:138-42.
  14. Alkin Z, Perente I, Altan C et al. Changes in anterior segment mor- phology after intravitreal injection of bevacizumab and bevacizumab- triamcinolone